Glaxo Smithkline posted EGP 3.666 million consolidated net profit for H1-14, with 53% fall compared with EGP 7.816 million in the year-ago period.
Standalone financial results for H1-14 showed EGP 4.453 million net profit, compared with EGP 8.006 million net profit in H1-13.
The company operates with EGP 835.14 million issued and paid-in capital, divided into 83.5 million shares at EGP 10 par value each.